The results of our study suggested that CD137 stimulation enhanced the anti-gastric-cancer effects of trastuzumab and cetuximab, and that CD137 expression was dependent upon mAb-binding affinity with Fc structures and FcγRIIIA polymorphisms. This evidence concerns the gene FCGR3A and gastric cancer.